Here's Why MannKind Corporation Remained Stuck in Reverse and Lost 24% in February
MannKind's reverse stock split gave investors the blues.
MannKind Corporation
MNKD
MNKD
MannKind Corporation
Interactive Chart
News & Analysis: MannKind Corporation
The Fool has written over 400 articles on MannKind Corporation.
Why MannKind Corporation Stock Is Sinking Today
The biopharma's reverse split isn't a hit with investors.
3 Stocks to Avoid in Biotech
Biotech stocks are known for their high growth, but they can also be toxic for your portfolio if you don't invest wisely.
Here's Why MannKind Corporation Rose 11.5% in January
A handful of positive developments caused shares to rally.
Good News and Bad News for MannKind Corporation
What does MannKind's update this week mean for investors?
Here's Why MannKind Corporation Is Plunging
Shares fell hard after management announced that a reverse stock split might be in the cards.
MannKind Has a New Plan, but Will It Work?
MannKind plans to more than double its sales force and air TV commercials plus more to increase Afrezza sales. Will this plan work?
Is MannKind Corp. Ready to Rebound in 2017?
MannKind's dreadful 2016 may have marked the beginning of the end of this struggling drugmaker.
Tax-Loss Selling: 3 Stocks to Dump Right Now
Arena Pharmaceuticals, MannKind Corp., and Dynavax Technologies Corp. may all be worth selling for tax purposes right now.
Better Buy: MannKind Corp. vs. Novo Nordisk
Which of these diabetes-focused companies is the better bet for new money today?
